Importance of protein-tyrosine phosphatase-alpha catalytic domains for interactions with SHP-2 and interleukin-1-induced matrix metalloproteinase-3 expression.
Interleukin-1 (IL-1) induces extracellular matrix degradation as a result of increased expression of matrix metalloproteinases (MMPs). We examined adhesion-restricted signaling pathways that enable IL-1-induced MMP release in human gingival and murine fibroblasts. Of the seven MMPs and three tissue inhibitors of MMPs screened, IL-1 enhanced release only of MMP3 when cells formed focal adhesions. Inhibition of protein-tyrosine phosphatases (PTPs), which are enriched in focal adhesions, blocked IL-1-induced MMP3 release. Accordingly, in contrast to wild-type cells, fibroblasts null for PTPalpha did not exhibit IL-1-induced MMP3 release. IL-1 treatment enhanced the recruitment of SHP-2 and PTPalpha to focal adhesions and the association of PTPalpha with SHP-2. Pulldown assays confirmed a direct interaction between PTPalpha and SHP-2, which was dependent on the intact, membrane-proximal phosphatase domain of PTPalpha. Interactions between SHP-2 and PTPalpha, recruitment of SHP-2 to focal adhesions, IL-1-induced ERK activation, and MMP3 expression were all blocked by point mutations in the phosphatase domains of PTPalpha. These data indicate that IL-1-induced signaling through focal adhesions leading to MMP3 release and interactions between SHP-2 and PTPalpha are dependent on the integrity of the catalytic domains of PTPalpha.
Wang
Qin
Q
Matrix Dynamics Group, University of Toronto, Toronto, Ontario M5S 3E2, Canada.
Rajshankar
Dhaarmini
D
Laschinger
Carol
C
Talior-Volodarsky
Ilana
I
Wang
Yongqiang
Y
Downey
Gregory P
GP
McCulloch
Christopher A
CA
D000818:Animals; D020134:Catalytic Domain; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000201:enzymology; D004789:Enzyme Activation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D022001:Focal Adhesions / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism*; D051379:Mice; D011485:Protein Binding / Q000187:drug effects; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11 / Q000378:metabolism*; D051381:Rats; D054630:Receptor-Like Protein Tyrosine Phosphatases, Class 4 / Q000737:chemistry* / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D013329:Structure-Activity Relationship
D007375:Interleukin-1; D048049:Extracellular Signal-Regulated MAP Kinases; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11; D054630:Receptor-Like Protein Tyrosine Phosphatases, Class 4; D019278:Matrix Metalloproteinase 3
Methods Mol Biol. 2004;273:169-78
15308801
Nature. 1995 Oct 12;377(6549):539-44
7566154
J Cell Sci. 2003 Nov 15;116(Pt 22):4605-13
14576354
EMBO J. 1999 May 4;18(9):2459-71
10228160
J Biol Chem. 1998 Nov 27;273(48):31890-900
9822658
Nat Genet. 1993 Jun;4(2):124-9
8348149
J Biol Chem. 1998 May 22;273(21):13223-9
9582366
Cell Signal. 2005 Nov;17(11):1323-32
16084691
Nature. 1996 Aug 8;382(6591):555-9
8700232
Trends Cell Biol. 2004 May;14(5):241-9
15130580
Biochem Biophys Res Commun. 1993 Jun 15;193(2):571-8
7685596
J Cell Physiol. 2006 Apr;207(1):132-43
16250012
Biochem Soc Trans. 2004 Jun;32(Pt3):416-20
15157150
EMBO J. 2000 Mar 1;19(5):964-78
10698938
J Biol Chem. 2000 Feb 4;275(5):3391-6
10652331
Am J Physiol Cell Physiol. 2008 Apr;294(4):C931-44
18216165
J Biol Chem. 1995 Mar 17;270(11):6042-9
7890736
Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46
17057753
J Biol Chem. 2005 Mar 4;280(9):8397-406
15563458
Cell. 2004 Jun 11;117(6):699-711
15186772
J Cell Biol. 2003 Apr 14;161(1):143-53
12682088
J Biol Chem. 1988 Jun 15;263(17):8261-9
2967293
Crit Rev Oral Biol Med. 1997;8(2):217-36
9167094
Mol Cell Biol. 1996 Dec;16(12):6887-99
8943344
J Cell Sci. 2007 Jan 1;120(Pt 1):137-48
17164291
J Biol Chem. 2009 Jul 31;284(31):20763-72
19497848
Mol Cell Biol. 1999 Apr;19(4):3205-15
10082587
Curr Biol. 1999 May 20;9(10):505-11
10339427
Cell. 2000 Oct 13;103(2):211-25
11057895
J Biol Chem. 2003 Jul 18;278(29):27190-8
12721296
J Biol Chem. 2006 Oct 13;281(41):31093-105
16905534
Nature. 1992 Sep 24;359(6393):336-9
1383828
J Cell Sci. 2003 Mar 15;116(Pt 6):975-86
12584242
Cell. 2005 Jun 3;121(5):667-70
15935753
J Rheumatol Suppl. 1995 Feb;43:123-8
7752115
Biochem J. 2000 Oct 1;351(Pt 1):95-105
10998351
J Biol Chem. 1998 Apr 10;273(15):8691-8
9535845
J Biol Chem. 1998 Aug 14;273(33):21125-31
9694867
J Biol Chem. 1998 Mar 20;273(12):7059-65
9507015
Biochem J. 1997 Jun 1;324 ( Pt 2):653-8
9182730
EMBO J. 2003 Oct 1;22(19):5023-35
14517241
Gynecol Obstet Invest. 1999;48 Suppl 1:2-13
10559659
Trends Cell Biol. 2001 Jun;11(6):258-66
11356362
Circ Res. 2004 Jun 25;94(12):1543-53
15217919
J Biol Chem. 2006 Apr 28;281(17):11972-80
16507567
Mol Biol Cell. 2000 Aug;11(8):2565-75
10930454
Front Biosci. 2002 Jan 01;7:d143-50
11779709
J Cell Biochem. 1992 Sep;50(1):53-61
1429874
Arthritis Res. 2002;4(3):157-64
12010565
J Biol Chem. 2000 Apr 28;275(17):12446-52
10777529
Curr Biol. 1999 May 20;9(10):535-8
10339428
J Cell Sci. 2001 Jan;114(Pt 1):119-129
11112696